Akèy › Myelofibroz › Massachusetts › Boston
Etid klinik pou Myelofibroz nan Boston, MA
12 etid pou Myelofibroz ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Ap rekriteFaz 3
- Tufts Medical Center, Boston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Ap rekriteFaz 1/2
- Massachusetts General Hospital (Data Collection Only), Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Ap rekriteFaz 1Volontè an sante akeyi
- Brigham and Women's Hospital, Boston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Momelotinib During and After HCT in Myelofibrosis
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Ap rekriteFaz 2Volontè an sante akeyi
- DFCI/BWH Brigham and Women's Hospital, Boston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Ap rekriteFaz 3
- Dana Farber Cancer Institute, Boston
Etid Myelofibroz nan lòt vil
- Houston, TX19 etid
- New York City, NY18 etid
- Durham, NC12 etid
- Columbus, OH11 etid
- Seattle, WA11 etid
- Miami, FL10 etid
- Salt Lake City, UT10 etid
- Atlanta, GA9 etid
- Tampa, FL9 etid
- Nashville, TN9 etid
- Cleveland, OH9 etid
- Baldwin Park, CA9 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.